Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Harmony Biosciences (Nasdaq: HRMY) will report its second quarter 2026 financial results on Tuesday, August 4, 2026, before U.S. market open.

Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) will report its second quarter 2026 financial results on Tuesday, August 4, 2026, before U.S. market open. The company will host a conference call and live webcast that day at 8:30 a.m. ET for investors and analysts.

Argus Jul 21 session 18 alerts

+9.97% close to close 1.3x rel. volume Open Argus

Details

News Market Reaction – HRMY

+5.9% Peak in 2 hr 22 min

$1.96B Market Cap

In the Jul 21 session, HRMY gained 9.97%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.9% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +10.0% in the session following this news. Historical earnings-date event 1044570 re...

Analysis

The stock moved +10.0% in the session following this news. Historical earnings-date event 1044570 recorded a 0.34% 24-hour move. A strong response would distinguish this notice from prior scheduling events. Risk context classified short positioning as low, limiting squeeze-related context.

Key Figures

Reporting period: Q2 2026 Results date: August 4, 2026 Conference call time: 8:30 a.m. ET

Reporting period

Q2 2026

Financial results

Results date

August 4, 2026

Before the open of U.S. financial markets

Conference call time

8:30 a.m. ET

Results discussion

Previous Earnings date Reports

2 past events · Latest: Apr 23

Same Type 2 events

1. Apr 23

   Earnings date notice

   24h Move

   +0.3%

   Scheduled Q1 2026 results and conference call for May 7

2. Feb 10

   Earnings date notice

   24h Move

   +2.3%

   Scheduled Q4 and full-year 2025 results for February 24

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Harmony Biosciences (HRMY) report Q2 2026 earnings?

Harmony Biosciences will report its Q2 2026 financial results on August 4, 2026, before U.S. markets open. According to Harmony Biosciences, the announcement will be accompanied by a conference call and webcast later that morning to discuss the results with investors.

What time is Harmony Biosciences' Q2 2026 earnings conference call on August 4, 2026?

The Q2 2026 earnings conference call for Harmony Biosciences is scheduled for 8:30 a.m. ET on August 4, 2026. According to Harmony Biosciences, investors can access the live call by phone or via webcast on the company’s investor relations website.

How can investors join the Harmony Biosciences (HRMY) Q2 2026 earnings call by phone?

Investors can join the Harmony Biosciences Q2 2026 call by dialing 800-347-6865 domestically or 203-518-9757 internationally. According to Harmony Biosciences, participants should reference passcode HRMYQ226 and are advised to dial in at least 10 minutes before the start.

Will Harmony Biosciences provide a webcast and replay for the Q2 2026 earnings call?

Yes, Harmony Biosciences will offer a live and replay webcast of its Q2 2026 earnings call. According to Harmony Biosciences, both live access and replay will be available through the investor page at https://ir.harmonybiosciences.com/ for convenient online listening.

Where can I find Harmony Biosciences investor relations information and Q2 2026 earnings webcast?

Harmony Biosciences directs investors to its investor relations website at https://ir.harmonybiosciences.com/ for the Q2 2026 earnings webcast. According to Harmony Biosciences, this page will host both the live stream and replay of the August 4, 2026 conference call.

Who are the investor and media contacts for Harmony Biosciences regarding Q2 2026 results?

For investor inquiries, Harmony Biosciences lists Brennan Doyle, phone 484-566-3685, email bdoyle@harmonybiosciences.com. According to Harmony Biosciences, media inquiries should be directed to Cate McCanless at 202-641-6086 or cmccanless@harmonybiosciences.com related to Q2 2026 communications.